WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Anticonvulsant legend, Repeated concepts/instances (e.g. Seizure occurrence) are denoted by dotted outline, Concepts (e.g. Seizure diary) are denoted by solid round-edged rectangle, Therapeutic Efficacy Endpoint Efficacy endpoints are evaluated in patients across clinical trials. Primary endpoints for determining efficacy of anticonvulsant therapy focus on seizure frequency, while secondary endpoints are characterized by other seizure frequency-related metrics, as well as patient quality of life., Therapeutic Efficacy Endpoint are characterized by Observations or Assessments, Primary efficacy endpoints (e.g. Seizure frequency) are denoted by bold font, Main concept groups (e.g. Primary efficacy endpoints) are denoted by Larger bold font with thicker outline, Endpoints currently under evaluation are denoted by Gray italicized font, Observations or Assessments Efficacy endpoints are characterized by sets of observations or assessments, usually made by patients or caregivers when noting different characteristics of seizures suffered by patients (e.g. frequency, severity, duration, etc.), Secondary efficacy endpoints (e.g. Development of new seizure types) are denoted by italics font